Early results from our Luxa Biotech-sponsored and #NEIfunded #ClinicalTrial are out in #CellStemCell. The trial uses an adult RPE stem cell therapy for dry age-related #MacularDegeneration.

Beautiful cover art by Dr. Yangzi Isabel Tian.

Full Text | zurl.co/gQ2bq
@cellpress.bsky.social
#NIHfunded

Safety and tolerability of RPESC-RPE transplantation in patients with dry age-related macular degeneration: Low-dose clinical outcomes Retinal pigment epithelium (RPE) cell loss in dry age-related macular degeneration leads to progressive vision decline. Stern and others implanted adult RPE stem cell-derived RPE progeny at a 4-week p...

Big news! Early results from Cohort 1 of our Luxa Biotechnology-sponsored and #NEIfunded clinical trial are now available online at Cell Stem Cell!

Open Access Full Text | zurl.co/piAT4

#NIHfunded #MacularDegeneration #ClinicalTrials

Single-cell transcriptome and surfaceome profiling of the adult human retinal pigment epithelium Farjood et al. has set the stage for characterizing RPE heterogeneity by using single-cell sequencing technology to identify cell surface markers compatible with isolating each subpopulation for furth...

Available now at @stemcellreports.bsky.social: Our #NEIfunded study led by Farhad Farjood, Nathan Boles and Jeffrey Stern reveals the surprising heterogeneity of retinal pigment epithelium cells in the human eye using single cell transcriptomics and proteomics.

R01 Notice of Award comes in, confetti canon comes out! Thank you @NatEyeInstitute
@UMassBoston
#vision
#research
#NEIfunded
🪰👀🧪

This is an amazing milestone in a 15+ year journey that began with discovery of the RPESC by Sally Temple & Jeffrey Stern.

#NEIfunded